Cancer Letters
Volume 241, Issue 1 , Pages 118-123 , 8 September 2006

Role of bone morphogenetic proteins in transitional cell carcinoma cells

  • Isaac Yi Kim

      Affiliations

    • Division of Urologic Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street #4560, New Brunswick, NJ 08903, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 732 235 5184.
    • ,
  • Seong Jin Kim

      Affiliations

    • Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD, USA

Received 26 September 2005 ,Revised 8 October 2005 ,Accepted 10 October 2005.

References 

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. CA Cancer J. Clin. 2005;55:10–30
  2. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N. Engl. J. Med. 1990;322:1129–1138
  3. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J. Urol. 2000;163:761–767
  4. Fontana D, Bellina M, Scoffone C, Cagnazzi E, Cappia S, Cavallo F, et al. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur. Urol. 1996;29:470–476
  5. Kroft SH, Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Lab. Invest. 1994;71:158–174
  6. Nagata Y, Abe M, Kobayashi K, Saiki S, Kotake T, Yoshikawa K, et al. Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn. J. Cancer Res. 1990;81:22–27
  7. Kotake T, Saiki S, Kinouchi T, Shiku J, Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn. J. Cancer Res. 1990;81:1198–1201
  8. Lipponen PK. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J. Pathol. 1995;175:203–210
  9. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644–1646
  10. Lee J, Dull TJ, Lax I, Schlessinger J, Ulrich A. HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. Eur. Mol. Biol. Org. J. 1989;8:167–173
  11. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kato T, Sato K, et al. Expression of c-erbB-2 gene product in urinary bladder cancer. J. Urol. 1991;145:423–427
  12. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R, Cooke T. C-erbB-2 gene amplification: molecular marker in recurrent bladder tumors?. Cancer Res. 1995;55:2422–2430
  13. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer. 1994;69:1120–1125
  14. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol. 1996;155:321–326
  15. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene. 1993;8:1083–1085
  16. Tokunaga H, Lee DH, Kim IY, Wheeler TM, Lerner SP. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin. Cancer Res. 1999;5:2520–2525
  17. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl Cancer Inst. 1992;84:1256–1261
  18. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 1992;84:1251–1256
  19. Lipponen PK. Overexpression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer. 1993;53:365–370
  20. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst. 1993;85:53–59
  21. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl Cancer Inst. 1993;85:241–242
  22. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J. Urol. 1999;161:799–804
  23. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl Cancer Inst. 1997;89:219–227
  24. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br. J. Cancer. 1998;77:650–655
  25. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528–1534
  26. Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, et al. Recombinant human osteogenic protein-1 (OP-1) induces bone formation. J. Biol. Chem. 1992;267:20352–20362
  27. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996;10:1580–1594
  28. Zhao G-Q. Consequences of knocking out BMP signaling in the mouse. Genesis. 2003;35:43–56
  29. Li F, Lu S, Vida L, Thomson JA, Honig GR. Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro. Blood. 2001;98:335–342
  30. Hager-theodorides AL, Outram SV, Shah DK, Sacedon R, Shrimpton RE, Vicente A, et al. Bone morphogenetic protein 2/4 signaling regulates early thymocyte differentiation. J. Immunol. 2002;169:5496–5504
  31. Holley SA, Neul JL, Attisano J, Wrana JL, Sasai Y, O'Connor MB, et al. The xenopus dorsalizing factor noggin ventralizes drosophila embryos by preventing DPP from activation its receptors. Cell. 1996;86:607–617
  32. Piccolo S, Sasai Y, Lu B, De Robertis EM. Dorsoventral patterning in xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell. 1996;589–598
  33. Liu F, Ventura F, Doody J, Massague J. Human type II receptor for bone morphogenetic proteins (BMPs); extension of the two-kinase receptor model to BMPs. Mol. Cell Biol. 1995;15:3479–3486
  34. Miyazono K, Maedab S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005;16:251–263
  35. Yamashita H, ten Dijke P, Heldin CH, Miyazono K. Bone morphogenetic protein receptors. Bone. 1996;19:569–574
  36. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl Acad. Sci. USA. 1995;92:7632–7636
  37. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Esterez M, Riddle DL, et al. Introduction of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem. 1994;269:16985–16988
  38. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, et al. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 1998;78:1219–1223
  39. Masuda H, Fukabori Y, Nakano K, Takezawa Y, Suzuki T, Yamanaka H. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. The Prostate. 2003;54:268–274
  40. Kim IY, Lee D-H, Ahn H-J, Tokunaga H, Song W, Devereaux LM, et al. Expression of bone morphogenetic protein receptors type-IA, -IB, and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res. 2000;60:2840–2844
  41. Kim IY, Lee DH, Ahn HJ, Kim MM, Morton RA. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene. 2004;23:7651–7659
  42. Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH, et al. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J. Pathol. 2005;206:366–376
  43. Nosho K, Yamamoto H, Adachi Y, Endo T, Hinoda Y, Imai K. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br. J. Cancer. 2005;92:1193–1200
  44. Yoshikawa H, Nakase T, Myoui A, Ueda T. Bone morphogenetic proteins in bone tumors. J. Orthop. Sci. 2004;9:334–340
  45. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 1997;57:5022–5027
  46. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J. Cell. Biochem. 2003;91:151–160
  47. Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene. 2004;23:9326–9335
  48. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P. Diverse biological effect and smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res. 2005;65:5769–5777
  49. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005;65:8274–8285
  50. Raida M, Clement JH, Ameri K, Han C, Lee RD, Harris AL. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int. J. Oncol. 2005;26:1465–1470
  51. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol. Cancer Res. 2004;2:141–149
  52. Pouliot F, Blais A, Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res. 2003;63:277–281
  53. Hallahan AR, Pritchard JI, Chandraratna RAS, Ellenbogen RG, Geyer JR, Overland RP, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat. Med. 2003;9:1033–1038
  54. Kawamura C, Kizaki M, Ikeda Y. Bone morphogenetic protein (BMP-2) induces apoptosis in human myeloma cells. Leuk. Lymphoma. 2002;43:635–639
  55. Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, et al. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin. Cancer Res. 2003;9:6046–6051
  56. Huang W, Rudkin GH, Carlsen B, Ishida K, Ghasri P, Anvar B, et al. Overexpression of BMP-2 modulates morphology, growth, and gene expression in osteoblastic cells. Exp. Cell Res. 2002;274:226–234
  57. Kim IY, Lee DH, Lee DK, Kim WJ, Kim MM, Morton RA, et al. Restoration of bone morphogenetic proteins receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line, TSU-Pr1. Cancer Res. 2004;64:7355–7360

PII: S0304-3835(05)00919-5

doi: 10.1016/j.canlet.2005.10.009

Cancer Letters
Volume 241, Issue 1 , Pages 118-123 , 8 September 2006

Article Tools

* Image Usage & Resolution